source
- CSL sinks to nine-year low on revenue warning, $5B write-downCSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by about 4% and said it would have to take a new $5 billion impairment charge. The ...Endpoints · 2mo ago↗ source
- Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate CancerThe regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.onclive · 2mo ago↗ source
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 2mo ago